All the fundraising deals in the longevity market (from Q2 2025 to Q2 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
The longevity market recorded 37 publicly disclosed funding rounds from Q2 2025 to Q2 2026.
These longevity startups raised approximately $1.64 billion across therapeutics, preventive-health platforms, diagnostics, clinics and consumer products.
Funding accelerated sharply in Q2 2026, although one $435 million NewLimit round represented most of the quarterly increase.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Longevity therapeutics attracted $1.02 billion, equal to 62% of all longevity market funding, as investors concentrated capital on cellular rejuvenation and treatments for biological aging.
- NewLimit raised $610 million across three rounds, representing 37% of all funding recorded in the longevity market during the five-quarter period.
- Q2 2026 was the strongest quarter, but NewLimit alone generated 68% of the quarter's $635.8 million funding total.
- Function Health showed that preventive-health platforms can attract large rounds when testing, clinical services, data and artificial intelligence are combined in one scalable membership product.
- The median-looking longevity startup still raised a relatively modest amount, despite an overall average deal size of $44.4 million that was lifted by several very large rounds.
- Animal longevity became a meaningful segment, with Loyal, Rejuvenate Bio and The Cat Health Company raising a combined $107.2 million.
- Consumer longevity funding increasingly favored products connected to measurable science, including peptides, fasting-mimicking nutrition and mTOR-related interventions.
- The top three rounds represented 52.5% of all longevity market funding, showing that investors placed large bets on a small number of perceived leaders.
- Q3 2025 had six funding deals but no round above $50 million, making the quarter broader and less dependent on a single major transaction.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
Summary table of the funding deals in the longevity market (last 5 quarters)
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the longevity market.
| Name | What they do | Amount in $ | Quarter |
|---|---|---|---|
| Juvenescence | Builds and finances medicines that target biological aging and age-related diseases. | $76M | Q2 2025 |
| NewLimit | Develops epigenetic medicines designed to restore youthful function in aging cells. | $130M | Q2 2025 |
| Biopeak | Operates Indian longevity clinics offering diagnostics, imaging and personalized medical programs. | $3.5M | Q2 2025 |
| NiaHealth | Combines biomarker testing with personalized preventive-health recommendations and long-term monitoring. | $5.75M | Q2 2025 |
| OneSkin | Develops peptide-based products intended to reduce cellular aging in the skin. | $20M | Q3 2025 |
| Fountain Life | Operates longevity centers that use imaging and biomarkers to detect disease early. | $18M | Q3 2025 |
| Molecular You | Analyzes blood biomarkers to identify health risks and guide preventive interventions. | $5M | Q3 2025 |
| Debut | Uses artificial intelligence and biomanufacturing to discover ingredients that target skin aging. | $20M | Q3 2025 |
| Circulate Health | Offers physician-supervised plasma exchange programs intended to improve biological-aging markers. | $12M | Q3 2025 |
| cellvie | Develops mitochondrial transplantation therapies to restore cellular energy and tissue function. | $5M | Q3 2025 |
| NewLimit | Develops epigenetic medicines designed to restore youthful gene activity in aging cells. | $45M | Q4 2025 |
| Generation Lab | Uses blood data to measure how quickly different organs are aging. | $11M | Q4 2025 |
| Function Health | Provides recurring laboratory testing, imaging and preventive-health insights through a membership platform. | $298M | Q4 2025 |
| Blueprint | Sells tests, supplements, food and protocols based on a measured longevity program. | $60M | Q4 2025 |
| Aeovian Pharmaceuticals | Develops selective mTORC1 medicines for diseases linked to aging-related cellular damage. | $55M | Q4 2025 |
| GlycanAge | Measures biological aging and inflammation through immune-system glycan patterns. | $8.7M | Q4 2025 |
| Junevity | Develops siRNA medicines that reset harmful gene activity associated with aging. | $10M | Q4 2025 |
| Lucis | Combines biomarker testing, artificial intelligence and personalized preventive-health recommendations. | $8M | Q4 2025 |
| Decode Age | Provides biological-age testing, microbiome analysis and longevity supplements. | $1.7M | Q4 2025 |
| The Cat Health Company | Develops medicines intended to extend feline healthspan and treat age-related diseases. | $1.2M | Q4 2025 |
| Engitix | Develops medicines that repair damaged tissue environments linked to aging and chronic disease. | $25M | Q1 2026 |
| Biopeak | Operates diagnostics-heavy longevity clinics and personalized health-optimization programs in India. | $2.7M | Q1 2026 |
| Juvena Therapeutics | Uses artificial intelligence to discover regenerative proteins that restore tissue function. | $33.5M | Q1 2026 |
| Loyal | Develops regulated medicines intended to extend healthy lifespan in dogs. | $100M | Q1 2026 |
| L-Nutra | Develops fasting-mimicking nutrition programs designed to improve metabolic health and healthspan. | $36.5M | Q1 2026 |
| TMRW | Provides Asia-Pacific longevity programs combining diagnostics, biological-age testing and functional medicine. | $7M | Q1 2026 |
| Ternary Therapeutics | Uses artificial intelligence to develop molecular glues targeting age-related inflammation. | $4.4M | Q1 2026 |
| Entourage AI | Develops proteomic tests that measure aging across individual organs. | $5M | Q1 2026 |
| Lucis | Provides ongoing biomarker testing, artificial intelligence analysis and personalized preventive-health guidance. | $20M | Q2 2026 |
| NewLimit | Develops epigenetic therapies intended to restore youthful function in aging cells. | $435M | Q2 2026 |
| Human Continuum | Develops exosome-based treatments and diagnostics for tissue repair and regenerative longevity. | $5.13M | Q2 2026 |
| Rejuvenate Bio | Develops gene therapies for age-related diseases in companion animals. | $6M | Q2 2026 |
| Life Biosciences | Develops partial cellular-reprogramming therapies intended to restore function in aged tissues. | $80M | Q2 2026 |
| HexemBio | Develops stem-cell treatments intended to restore aging blood and immune systems. | $10.4M | Q2 2026 |
| Everlab | Combines diagnostics, physician review and artificial intelligence to identify health risks early. | $42.25M | Q2 2026 |
| Gero | Uses human data and artificial intelligence to discover drug targets linked to aging. | $17M | Q2 2026 |
| Rapalogix Health | Develops TORC1-based products and therapies that target cellular mechanisms of skin aging. | $20M | Q2 2026 |
In our longevity market deck, we identify pain points entrepreneurs should prioritize
How has funding activity in the longevity market changed over time?
Q2 2026 was the strongest quarter, with $635.8 million raised, but NewLimit's $435 million Series C generated most of that total.
Q3 2025 was the least active quarter by value, as six longevity market deals raised $80 million and none exceeded $50 million.
Longevity market funding increased by 197% from Q1 2026 to Q2 2026 and by 195% compared with Q2 2025.
The underlying trend is steadier when the largest rounds are removed. Excluding the two biggest deals in each quarter, funding rose more gradually and Q4 2025 had the strongest remaining total.
| Quarter | Number of deals | Total raised ($) | Comment |
|---|---|---|---|
| Q2 2025 | 4 | $215M | NewLimit and Juvenescence represented almost all longevity market funding during the quarter. |
| Q3 2025 | 6 | $80M | Funding was spread across six smaller deals, with no round above $50 million. |
| Q4 2025 | 10 | $499M | Function Health drove the total, while nine other startups created the broadest quarter. |
| Q1 2026 | 8 | $214M | Loyal led a balanced quarter that also included nutrition, regenerative medicine and diagnostics. |
| Q2 2026 | 9 | $636M | NewLimit produced 68% of funding, although eight other companies still raised $201 million. |
| All quarters | 37 | $1.64B | Longevity market funding was active but heavily influenced by a few exceptionally large rounds. |
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
Which startups in the longevity market raised the largest rounds over the last months?
These startups raised the most recently in the longevity market:
- NewLimit raised $435 million to begin human trials and expand epigenetic-reprogramming programs into more age-related conditions.
- Function Health raised $298 million to scale its testing, imaging, clinical and artificial-intelligence infrastructure for preventive care.
- NewLimit raised $130 million to expand its scientific team and move liver-cell rejuvenation programs closer to clinical development.
- Loyal raised $100 million to complete regulatory, manufacturing and launch preparations for medicines designed to extend healthy lifespan in dogs.
- Life Biosciences raised $80 million to finance clinical development of cellular-reprogramming therapies, including treatments for age-related eye conditions.
- Juvenescence raised $76 million to advance clinical programs and establish an artificial-intelligence-enabled drug-development hub in Abu Dhabi.
- Blueprint raised $60 million to expand its longevity products, research, distribution network and wider health-optimization ecosystem.
- Aeovian Pharmaceuticals raised $55 million to move its selective mTORC1 medicine through clinical development and expand its aging-focused pipeline.
- NewLimit raised $45 million to accelerate its liver programs and prepare its first cellular-reprogramming candidate for clinical testing.
- Everlab raised approximately $42.25 million to enter the United Kingdom and expand its preventive diagnostics and artificial-intelligence platform.
And, yes, we do cover most of them in our our beautiful pitch about the longevity market.
You may also want to check our ranking of the most funded startups in the longevity market as well as our list of the most valued startups.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Is the longevity market shifting toward smaller or bigger deals?
The average longevity market funding round was $44.4 million across the five quarters, but several very large rounds lifted this figure.
Average deal size ranged from $13.3 million in Q3 2025 to $70.6 million in Q2 2026. The difference mainly reflects the timing of large NewLimit and Function Health rounds.
Without the largest outliers, the longevity market shows a more gradual increase in funding rather than a clear shift toward consistently bigger deals.
| Quarter | Number of deals | Average deal size | Deals below $2M | Deals above $50M |
|---|---|---|---|---|
| Q2 2025 | 4 | $53.81M | 0 | 2 |
| Q3 2025 | 6 | $13.33M | 0 | 0 |
| Q4 2025 | 10 | $49.86M | 2 | 3 |
| Q1 2026 | 8 | $26.76M | 0 | 1 |
| Q2 2026 | 9 | $70.64M | 0 | 2 |
| All quarters | 37 | $44.43M | 2 | 8 |
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
How concentrated was funding activity in the longevity market?
Funding in the longevity market was highly concentrated, as the largest deal generated more than half of quarterly funding in Q2 2025, Q4 2025 and Q2 2026. The top three deals captured at least 72.5% in every quarter.
This concentration means quarterly totals can rise sharply even when funding conditions for the average longevity startup change only slightly.
| Quarter | Number of deals | Top 1 share | Top 3 share | Top 10 share |
|---|---|---|---|---|
| Q2 2025 | 4 | 60.4% | 98.4% | 100.0% |
| Q3 2025 | 6 | 25.0% | 72.5% | 100.0% |
| Q4 2025 | 10 | 59.8% | 82.8% | 100.0% |
| Q1 2026 | 8 | 46.7% | 79.4% | 100.0% |
| Q2 2026 | 9 | 68.4% | 87.6% | 100.0% |
| All quarters | 37 | 26.5% | 52.5% | 80.4% |
This chart, featured in our longevity market deck, illustrates how revenue is distributed across customer segments in the longevity market
Which categories in the longevity market received the most funding?
Longevity therapeutics raised $1.02 billion, or 62.2% of all funding, because drug development and clinical trials require substantial capital. NewLimit's three rounds were the largest contributor.
Preventive-health platforms raised $374 million, or 22.8% of the longevity market total. Function Health showed that integrated testing and clinical platforms can scale beyond individual clinics.
Consumer-longevity brands raised $138.2 million, or 8.4% of total funding. Investors favored products linked to specific biological mechanisms and measurable health outcomes.
| Category name | Number of deals | Total raised ($) | Startups and amount |
|---|---|---|---|
| Longevity therapeutics | 16 | $1.02B | NewLimit $610M; Juvenescence $76M; cellvie $5M; Junevity $10M; Aeovian Pharmaceuticals $55M; The Cat Health Company $1.2M; Engitix $25M; Juvena Therapeutics $33.5M; Loyal $100M; Ternary Therapeutics $4.4M; Human Continuum $5.13M; Rejuvenate Bio $6M; Life Biosciences $80M; HexemBio $10.4M |
| Preventive-health platforms | 5 | $374M | NiaHealth $5.75M; Function Health $298M; Lucis $28M across two rounds; Everlab $42.25M |
| Consumer-longevity brands | 5 | $138.2M | OneSkin $20M; Blueprint $60M; Decode Age $1.7M; L-Nutra $36.5M; Rapalogix Health $20M |
This chart, featured in our longevity market deck, shows how longevity plan technology has evolved over time
Who are the biggest investors in the longevity market?
Kleiner Perkins participated in three NewLimit rounds totaling $610 million, making the firm one of the most active disclosed longevity market investors.
Human Capital also participated in three NewLimit rounds totaling $610 million, reflecting a long-term commitment to cellular-reprogramming technology.
Left Lane Capital appeared across three preventive-health companies connected to approximately $360.25 million in disclosed funding.
Eli Lilly Ventures and Eli Lilly backed NewLimit and Juvena Therapeutics, connecting a major pharmaceutical group with cellular rejuvenation and regenerative biologics.
NFDG participated in Function Health and NewLimit rounds totaling $733 million, spanning preventive-health infrastructure and longevity therapeutics.
Duke Management Company participated in two NewLimit rounds totaling $480 million.
Founders Fund participated in two NewLimit rounds totaling $565 million, including the company's $435 million Series C.
Khosla Ventures backed Circulate Health and Loyal, linking human plasma-exchange programs with regulated animal-longevity medicines.
Disclaimer: this investor list may be incomplete; we focus on publicly disclosed lead and prominent recurring investors, so some frequent minority participants may be underrepresented. “Total funded” does not represent the amount personally invested by an individual investor. Instead, it refers to the aggregate amount raised across all fundraising rounds in which the investor participated.
| Investor | Number of deals | Total funded ($) | Startups |
|---|---|---|---|
| Kleiner Perkins | 3 | $610M | NewLimit |
| Human Capital | 3 | $610M | NewLimit |
| Left Lane Capital | 3 | $360.25M | Function Health, Lucis, Everlab |
| NFDG | 2 | $733M | Function Health, NewLimit |
| Founders Fund | 2 | $565M | NewLimit |
| Duke Management Company | 2 | $480M | NewLimit |
| Eli Lilly Ventures / Eli Lilly | 2 | $468.5M | NewLimit, Juvena Therapeutics |
| Khosla Ventures | 2 | $112M | Circulate Health, Loyal |
This chart, featured in our longevity market deck, shows how wearable longevity devices have driven growth in the longevity market over time
Related blog posts
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
- How strong is fundraising in the longevity market right now?
